Last reviewed · How we verify
CT-P17 SC AI (adalimumab)
CT-P17 SC AI (adalimumab) is a TNF-α inhibitor (monoclonal antibody biosimilar) Biologic drug developed by Celltrion. It is currently in Phase 3 development for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
CT-P17 SC AI is a subcutaneous adalimumab biosimilar that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
CT-P17 SC AI is a subcutaneous adalimumab biosimilar that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | CT-P17 SC AI (adalimumab) |
|---|---|
| Sponsor | Celltrion |
| Drug class | TNF-α inhibitor (monoclonal antibody biosimilar) |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that binds to and neutralizes TNF-α, a key pro-inflammatory cytokine. By inhibiting TNF-α signaling, it suppresses the inflammatory cascade underlying autoimmune and inflammatory diseases. CT-P17 SC AI is Celltrion's subcutaneous formulation of this established mechanism, designed for improved patient convenience.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- Plaque psoriasis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Nausea
- Serious infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P17 SC AI (adalimumab) CI brief — competitive landscape report
- CT-P17 SC AI (adalimumab) updates RSS · CI watch RSS
- Celltrion portfolio CI
Frequently asked questions about CT-P17 SC AI (adalimumab)
What is CT-P17 SC AI (adalimumab)?
How does CT-P17 SC AI (adalimumab) work?
What is CT-P17 SC AI (adalimumab) used for?
Who makes CT-P17 SC AI (adalimumab)?
What drug class is CT-P17 SC AI (adalimumab) in?
What development phase is CT-P17 SC AI (adalimumab) in?
What are the side effects of CT-P17 SC AI (adalimumab)?
What does CT-P17 SC AI (adalimumab) target?
Related
- Drug class: All TNF-α inhibitor (monoclonal antibody biosimilar) drugs
- Target: All drugs targeting TNF-α (tumor necrosis factor-alpha)
- Manufacturer: Celltrion — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Psoriatic arthritis
- Indication: Drugs for Ankylosing spondylitis
- Compare: CT-P17 SC AI (adalimumab) vs similar drugs
- Pricing: CT-P17 SC AI (adalimumab) cost, discount & access